Israeli microbiome company BiomX has exclusively sub-licensed from JSR Corp (TYO: 4185) a set of bacterial targets for the development and commercialization of phage therapies that eradicate these targets, as a treatment for inflammatory bowel disease (IBD).
These targets, discovered by Dr Kenya Honda, Professor of Microbiology and Immunology at Keio University School of Medicine, were shown to be pro-inflammatory and may have a role in the onset and aggravation of IBD. The findings were recently published in Science magazine.
Although no financial terms of the accord were revealed, JSR’s shares were up 12.7% at 2,645 yen by close of Japanese trading today.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze